Increased survival using platinum analog combined with gemcitabine as compared to single-agent gemcitabine in advanced pancreatic cancer: pooled analysis of two randomized trials, the GERCOR/GISCAD intergroup study and a German multicenter study-Reference-Cited by-同舟云学术

Increased survival using platinum analog combined with gemcitabine as compared to single-agent gemcitabine in advanced pancreatic cancer: pooled analysis of two randomized trials, the GERCOR/GISCAD intergroup study and a German multicenter study

Published:2007-10 Issue:10 Volume:18 Page:1652-1659
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Heinemann V.,Labianca R.,Hinke A.,Louvet C.

Publisher

Elsevier BV

Subject

Oncology,Hematology

Link

http://academic.oup.com/annonc/article-pdf/18/10/1652/309292/mdm283.pdf

Reference35 articles.

1. Cancer of the pancreas;Evans,2001

2. Pancreatic carcinoma;Rosewicz;Lancet,1997

3. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial;Burris;J Clin Oncol,1997

4. Chemotherapy for advanced pancreatic cancer;Haller;Int J Radiat Oncol Biol Phys,2003

5. Gemcitabine-based combination treatment of pancreatic cancer;Heinemann;Semin Oncol,2002

Cited by 95 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Effect of adding Schroth physiotherapeutic scoliosis specific exercises to standard care in adolescents with idiopathic scoliosis on posture assessed using surface topography: A secondary analysis of a Randomized Controlled Trial (RCT);PLOS ONE;2024-04-30

2. pH-responsive targeted nanoparticles release ERK-inhibitor in the hypoxic zone and sensitize free gemcitabine in mutant K-Ras-addicted pancreatic cancer cells and mouse model;PLOS ONE;2024-04-30

3. pH-responsive Targeted nanoparticles release ERK-inhibitor in the hypoxic zone Sensitizes Gemcitabine in Mutant K-Ras-addicted Pancreatic Cancer;2023-05-15

4. Performance status as prognostic factor in phase III trials of first‐line chemotherapy of unresectable or metastatic pancreatic cancer: A trial‐level meta‐analysis;Asia-Pacific Journal of Clinical Oncology;2021-06-23

5. Pancreatic Adenocarcinoma, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology;Journal of the National Comprehensive Cancer Network;2021-04